MX2015015115A - Metodos de tratamiento de cancer. - Google Patents

Metodos de tratamiento de cancer.

Info

Publication number
MX2015015115A
MX2015015115A MX2015015115A MX2015015115A MX2015015115A MX 2015015115 A MX2015015115 A MX 2015015115A MX 2015015115 A MX2015015115 A MX 2015015115A MX 2015015115 A MX2015015115 A MX 2015015115A MX 2015015115 A MX2015015115 A MX 2015015115A
Authority
MX
Mexico
Prior art keywords
fgfr1
methods
overexpression
ecd
fusion molecule
Prior art date
Application number
MX2015015115A
Other languages
English (en)
Inventor
Julie Hambleton
Rakesh Kumar
Maureen R Bleam
Maurice P Deyoung
Geraldine Ferron-Brady
Lone Ottesen
Original Assignee
Five Prime Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Five Prime Therapeutics Inc filed Critical Five Prime Therapeutics Inc
Publication of MX2015015115A publication Critical patent/MX2015015115A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Se proporcionan métodos de tratamiento de cánceres que comprenden amplificación del gen de FGFR1, sobreexpresión de FGFR1, sobreexpresión de FGFR3, amplificación de FGFR3, sobreexpresión de FGP2, y/o amplificación del gen de FGF2. En algunas modalidades, los métodos comprenden administrar un dominio extracelular (ED) del receptor del factor del crecimiento Fibroblástico 1 (EGFR1) y/o una molécula de fusión de ECD de FGFR1. En algunas modalidades, el método comprende administrar un ECD de FGFR1 y/o una molécula de fusión de ECD de FGFR1 en combinación con al menos un agente terapéutico adicional. En algunas modalidades, se proporcionan métodos del tratamiento de cánceres que comprenden administrar un ECD de FGFR1 y/o una molécula de fusión de ECD de FGFR1 en combinación con al menos un agente quimioterapéutico.
MX2015015115A 2013-05-01 2014-04-30 Metodos de tratamiento de cancer. MX2015015115A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361818220P 2013-05-01 2013-05-01
US201361831029P 2013-06-04 2013-06-04
PCT/US2014/036140 WO2014179448A2 (en) 2013-05-01 2014-04-30 Methods of treating cancer

Publications (1)

Publication Number Publication Date
MX2015015115A true MX2015015115A (es) 2016-06-07

Family

ID=50928263

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015015115A MX2015015115A (es) 2013-05-01 2014-04-30 Metodos de tratamiento de cancer.

Country Status (13)

Country Link
US (2) US20160067307A1 (es)
EP (1) EP2991669A2 (es)
JP (1) JP2016526016A (es)
KR (1) KR20160003141A (es)
CN (1) CN105188732A (es)
AU (1) AU2014259956A1 (es)
BR (1) BR112015027607A8 (es)
CA (1) CA2908391A1 (es)
HK (1) HK1213817A1 (es)
MX (1) MX2015015115A (es)
RU (1) RU2015150233A (es)
SG (1) SG11201508878WA (es)
WO (1) WO2014179448A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2614039C (en) 2005-07-22 2015-10-13 Five Prime Therapeutics, Inc. Compositions and methods of treating disease with fgfr fusion proteins
US8481038B2 (en) 2010-11-15 2013-07-09 Five Prime Therapeutics, Inc. Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins
EP2780033B1 (en) 2011-11-14 2019-05-08 Five Prime Therapeutics, Inc. An fgfr1 extracellular domain for use in the treatment of cancer with an fgfr1 gene amplification
PT3027651T (pt) 2013-08-01 2019-05-31 Five Prime Therapeutics Inc Anticorpos anti-fgfr2iiib não fucosilados
WO2017017516A1 (en) * 2015-07-24 2017-02-02 Debiopharm International Sa Fgfr expression and susceptibility to an fgfr inhibitor
WO2017091580A1 (en) * 2015-11-23 2017-06-01 Five Prime Therapeutics, Inc. Predicting response to cancer treatment with fgfr2 inhibitors
PL238516B1 (pl) 2016-06-13 2021-08-30 Univ Wroclawski Sposób otrzymywania modyfikowanego polipeptydu
CN110785184A (zh) * 2017-02-06 2020-02-11 雷尼尔医疗公司 用于治疗癌症的方法，组合物和试剂盒
WO2018195273A1 (en) * 2017-04-19 2018-10-25 The Corporation Of Mercer University Sam-1 protein, composition and methods of use
CA3062177A1 (en) 2017-05-16 2018-11-22 Five Prime Therapeutics, Inc. Anti-fgfr2 antibodies in combination with chemotherapy agents in cancer treatment

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US5700637A (en) 1988-05-03 1997-12-23 Isis Innovation Limited Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays
WO1990006952A1 (en) 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
SG89295A1 (en) 1991-03-15 2002-06-18 Amgen Inc Pegylation of polypeptides
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5807522A (en) 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
US6573043B1 (en) 1998-10-07 2003-06-03 Genentech, Inc. Tissue analysis and kits therefor
WO2000025803A1 (fr) 1998-10-30 2000-05-11 Takeda Chemical Industries, Ltd. Preparations contenant une proteine betacelluline
AU2001249727A1 (en) 2000-03-31 2001-10-15 Genentech, Inc. Compositions and methods for detecting and quantifying gene expression
ES2331646T3 (es) 2000-05-19 2010-01-12 Genentech, Inc. Ensayo para la deteccion de genes para mejorar la probabilidad de una respuesta eficaz a una terapia contra el cancer basada en antagonistas de erbb.
US20050209310A1 (en) * 2000-12-22 2005-09-22 Chaplin David J Methods for modulating tumor growth and metastasis
US6900292B2 (en) 2001-08-17 2005-05-31 Lee-Hwei K. Sun Fc fusion proteins of human erythropoietin with increased biological activities
PT1638941E (pt) 2003-05-22 2010-08-24 Abbott Lab Inibidores de quinases de indazole, benzisoxazole e benzisotiazole
WO2006076288A2 (en) 2005-01-11 2006-07-20 Five Prime Therapeutics, Inc. Dna constructs for long-term expression of intravascularly injected naked dna
CA2614039C (en) 2005-07-22 2015-10-13 Five Prime Therapeutics, Inc. Compositions and methods of treating disease with fgfr fusion proteins
CA2626679C (en) * 2005-11-04 2011-08-16 Merck & Co., Inc. Methods of treating cancers with saha, carboplatin, and paclitaxel and other combination therapies
ES2342646B1 (es) 2008-06-02 2011-04-26 Institut De Recerca Hospital Universitari Vall Hebron Metodo de diagnostico de canceres que expresan el receptor her-2 o sus variantes truncadas.
CA2817583A1 (en) * 2010-11-15 2012-05-24 Five Prime Therapeutics, Inc. Treatment of cancer with elevated dosages of soluble fgfr1 fusion proteins
US8481038B2 (en) * 2010-11-15 2013-07-09 Five Prime Therapeutics, Inc. Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins
US8951972B2 (en) * 2010-12-09 2015-02-10 Five Prime Therapeutics, Inc. FGFR1 extracellular domain combination therapies for lung cancer
EP2780033B1 (en) * 2011-11-14 2019-05-08 Five Prime Therapeutics, Inc. An fgfr1 extracellular domain for use in the treatment of cancer with an fgfr1 gene amplification

Also Published As

Publication number Publication date
WO2014179448A3 (en) 2014-12-24
BR112015027607A2 (pt) 2017-12-05
US20160067307A1 (en) 2016-03-10
US20180280470A1 (en) 2018-10-04
RU2015150233A (ru) 2017-06-02
CN105188732A (zh) 2015-12-23
AU2014259956A1 (en) 2015-11-12
CA2908391A1 (en) 2014-11-06
WO2014179448A2 (en) 2014-11-06
HK1213817A1 (zh) 2016-07-15
KR20160003141A (ko) 2016-01-08
JP2016526016A (ja) 2016-09-01
SG11201508878WA (en) 2015-11-27
BR112015027607A8 (pt) 2018-01-23
EP2991669A2 (en) 2016-03-09

Similar Documents

Publication Publication Date Title
MX2015015115A (es) Metodos de tratamiento de cancer.
AU2018201942B2 (en) Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
MX2017003246A (es) Macropinocitosis de anticuerpos anti-cd46 humanos y agentes terapeuticos dirigidos contra el cancer.
CL2008003846A1 (es) Uso de compuestos derivados de 1,2,4-triazolo condensado con heterociclos, los cuales actuan como ligados del receptor de androgeno (ar); compuestos; proceso de preparacion; composicion farmaceutica y el uso de dichos compuestos para el tratamiento del cancer de prostata.
AU2018265888A1 (en) Use of anti-B7H3 antibodies for treating cancer in the central nervous system
BR112015009752A2 (pt) conjugados de anticorpo/fármaco e métodos de uso
CL2008002097A1 (es) Compuestos derivados de heterociclos condensados sustituidos, inhibidores de cinasa de fosfatidil-inositol-3; composicion farmaceutica; y uso en el tratamiento del cancer.
MY177989A (en) Lna oligonucleotide carbohydrate conjugates
MX2015008898A (es) Metodos para el tratamiento de cancer pancreatico.
MX2010010480A (es) Metodos de tratamiento o prevencion del cancer colorrectal.
MX2015008685A (es) Tratamiento de artritis psoriasica usando apremilast.
MX2018001511A (es) Polimeros furtivos desordenados de forma intrinseca codificados geneticamente para suministro y metodos para usar los mismos.
MX2014005800A (es) Mutaciones del receptor notch humano y su uso.
WO2008094319A3 (en) Methods and compositions of trail-death receptor agonists/activators
SG10201903112WA (en) Treatment of cancer using coenzyme q10 combination therapies
SA515370134B1 (ar) تركيبة صيدلانية تحتوي على عامل علاجي قائم على الهيموغلوبين المعدل لعلاج السرطان المستهدف والتصوير التشخيصي
EP3895725A3 (en) A method for treating tumor by using recombinant interferon with changed spatial configuration
SG10201907816RA (en) Methods of treatment of cancer by continuous infusion of coenzyme q10
EP3242688A4 (en) Cox-2-targeting, platinum-containing conjugates and their use in the treatment of tumors and cancers
EA201101651A1 (ru) Непрерывное введение интегриновых лигандов для лечения рака
BR112015005443A2 (pt) tratamento combinado com fármaco interferente de netrina-1 e fármaco quimioterápico
WO2018208954A3 (en) Peptidomimetic macrocycles and uses thereof
MX2015015426A (es) Metodos de tratamiento de cancer.
PH12015502266A1 (en) Methods and compositions using 4-amino-2-(2,6-dioxo-piperidine-3-yl)-isoindoline-1,3-dione for treatment and management of central nervous system cancers
WO2011056566A3 (en) Compounds and methods for treatment of cancer